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12Changes in Quality-of-Life and Psychosocial
Adjustment among Multiple Myeloma Patients Treated
with High-Dose Melphalan and Autologous
Stem Cell Transplantation
Allen C. Sherman, PhD,1 Stephanie Simonton, PhD,1 Umaira Latif, MSc,3
Thomas G. Plante, PhD,4 Elias J. Anaissie, MD2High-dosemelphalan and autologous hematopoietic stem cell transplantation (HSCT) is a standard treatment
for myeloma, but very little is known about the psychosocial or quality-of-life difficulties that these patients
encounter during treatment. Data regarding older patients is particularly scarce. Using a prospective design,
this investigation evaluated 94 patients at stem cell collection and again after high-dose therapy and transplan-
tation. Outcomes included quality-of-life (FACT-BMT) and psychosocial adjustment (ie, Brief Symptom Inven-
tory, Impact of Events Scale, and Satisfaction with Life Scale). Findings were compared with age- and
sex-adjusted population norms and with transplantation patient norms. At stem cell collection, physical def-
icitswere common,withmost patients scoring 1 standard deviation belowpopulation norms for physical well-
being (70.2%) and functionalwell-being (57.5%), andmany reporting at leastmoderate fatigue (94.7%) and pain
(39.4%). Clinically meaningful levels of anxiety (39.4%), depression (40.4%), and cancer-related distress
(37.0%) were evident in a notable proportion of patients. After transplantation, there was a worsening of
transplant-related concerns (P\ .05), depression (P\ .05), and life-satisfaction (P\ .001); however, pain
improved (P\.01), and social functioning was well preserved. Overall, the declines in functioning after trans-
plantation were less pronounced than anticipated. Older patients were notmore compromised than younger
ones; in multivariate analyses, they reported better overall quality of life (P\.01) and less depression (P\.05)
before transplantation. Our findings emphasize the importance of early screening and intervention.
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adjustmentAlthough an expanding literature has examined
quality-of-life outcomes for patients undergoing
hematopoietic stem cell transplantation (HSCT),
very few studies have focused on the experience of pa-
tients with multiple myeloma. High-dose therapy fol-
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6/j.bbmt.2008.09.023has become a front-line treatment for myeloma [1-3].
However, there is little systematic information about
the functional and behavioral sequelae that these pa-
tients experience during the course of therapy.
Multiple myeloma, a malignancy of plasma cells, is
the second most common hematologic cancer [4].
Characteristic features include lytic bone lesions, com-
pression fractures, hypercalcemia, anemia, and renal
dysfunction. Consequently, health-related quality of
life (HRQOL) often is compromised by pain, fatigue,
and disrupted role functioning—difficulties that may
be further compounded by the demanding toxicities
associated with HSCT. Research is needed to charac-
terize the prevalence and trajectory of HRQOL
changes in order to better inform patients and guide
interventions.
One of the few studies to examine HRQOL in my-
eloma patients in the transplantation setting was con-
ducted by the Nordic Myeloma Study Group [5-7].
In a nonrandomized study using historical controls,
patients treated with high-dose melphalan and
Biol Blood Marrow Transplant 15:12-20, 2009 13Quality-of-Life in Multiple Myeloma PatientsHSCT were compared retrospectively with patients
who had received conventional treatment with mel-
phalan and prednisone on an earlier protocol. Before
treatment, both patient groups scored significantly
worse in almost all domains relative to healthy popula-
tion norms, as assessed by the EORTC-QOL-Q30 [7].
Once treatment began, the transplantation patients
fared more poorly initially than the historical controls
who had received conventional therapy (eg, poorer
role functioning and global quality of life [QOL]), as
might be expected [5]. But by the 24- and 36-month
follow-ups, scores had generally improved and were
comparable between the 2 groups [5,7]. Despite pro-
gressively improved functioning over time, however,
patients undergoing transplantation still demonstrated
notable deficits in physical, role, and social function-
ing, as well as modest difficulties with pain and fatigue,
compared with healthy population norms [7].
The Nordic Myeloma Study Group investigations
provided salient findings from a large, multicenter
study. However, the protocol excluded patients age
60 and over, who traditionally were considered unable
to tolerate HSCT. Myeloma is predominately a disease
of the elderly, and currently many older patients un-
dergo transplantation [8,9]; there is a pressing need
to examine outcomes for these individuals. Moreover,
the study did not present findings for the acute post-
transplantation period, a critical interval during which
HRQOL deficits generally are most pronounced (due
to neutropenia, infection, mucositis, etc). Although
these difficulties diminish for most patients, informa-
tion during this interval is needed to guide clinicians
in providing appropriate care. Finally, the study pro-
vided very limited data about psychosocial outcomes
(eg, depression, anxiety), which are important, al-
though neglected, targets for intervention.
In our previous work, we examined psychosocial
adjustment and HRQOL during the early diagnostic
period in a large sample of myeloma patients, who var-
ied widely widely in age [10,11]. Our data indicated
a high prevalence of difficulties in multiple domains
of functioning before the initiation of induction ther-
apy [11]. In a more recent investigation, Anderson
et al. [12,13] evaluated patients as they progressed
through HSCT. As anticipated, symptom burden in-
creased over the course of treatment, peaking in sever-
ity in the acute posttransplantation period (ie, leukocyte
nadir); symptoms subsequently improved, but there
were areas of continued difficulty (eg, nausea, weakness,
appetite). Psychosocial outcomes were included in this
study, but analyses were limited to a few single-item in-
dices. Clearly, further research is needed.
The aim of the current study was to characterize
changes in diverse domains of functioning during an in-
tensive phase of treatment. We used a prospective de-
sign and validated measures to evaluate patients
during stem cell collection (ie, after beginning induc-tion chemotherapy) and then again in the immediate af-
termath of transplantation. These are pivotal phases of
care, during which patients are expected to experience
considerable deficits. Specifically, we examined
HRQOL (ie, physical, functional, social, and emotional
well being and transplantation-related concerns) and
psychosocial adjustment (ie, depression, anxiety, ill-
ness-related distress, life satisfaction). To help interpret
our findings, we compared outcomes with both healthy
population norms and transplantation patient norms. A
secondary aim was to evaluate medical and demo-
graphic correlates of these outcomes, in order to iden-
tify patient subgroups at heightened risk (particularly
older individuals). We expected our findings to provide
a foundation for subsequent longer-term studies.PATIENTS AND METHODS
Patients
The participants were 94 myeloma patients receiv-
ing treatment at the Myeloma Institute for Research
and Therapy between March 1999 and September
2002. Patients were eligible for the study if they were
undergoing stem cell collection for autologous
HSCT. Exclusion criteria included hematologic ma-
lignancies other than myeloma, concurrent malignan-
cies, planned allogeneic transplantation (because this
treatment differs notably from autologous HSCT),
and cognitive or functional limitations sufficiently
severe to preclude completion of questionnaires. Eigh-
teen of 153 patients declined to participate (88%
accrual). Of the 135 patients enrolled, 41 were not in-
cluded in the analyses because they did not receive the
posttransplantation assessment; reasons included not
proceeding to autologous HSCT (n 5 28), declining
of the second assessment (n 5 9), or terminal condi-
tion/severely impaired performance status (n 5 4).
During this period, additional patients were treated
at the center but were not assessed because of logistic
considerations. The patients who declined enrollment
did not differ from the participants in terms of any of
the clinical or demographic variables assessed. More-
over, the patients who completed the study did not
differ from those who did not, except that the non-
completers (most of whom who did not proceed to
transplantation) were more likely to have been treated
off protocol (P\ .0001).
Sample characteristics are listed in Table 1. Sixty-
two percent of the participants were male, and the
median time since diagnosis was 6 months (range, 2
to 120). Most patients were treated with 1 of 2 proto-
cols: 56% were enrolled on total therapy 2 [14], which
involved induction treatment with VAD (vincristine,
doxorubicin, and dexamethasone), DCEP (cyclo-
phosphamide, etoposide, cisplatin, and dexametha-
sone), CAD (cyclophosphamide, doxorubicin, and
Table 1. Sample Characteristics
Characteristic n (%) Characteristic
Mean (SD)
(Range)
Marital status Age, years 55.7 (9.2)
Married 77 (81.9) (34 to 74)
Not married 17 (18.1)
Sex Education, years 15.1 (2.8)
Male 58 (61.7) (10 to 23)
Female 36 (38.3)
Ethnicity/race Months since
White 86 (91.5) initial diagnosis 13.1 (21.7)
Other 8 (8.5) (2 to 120)
Stage*
I 17 (18.1)
II 5 (5.3)
III 67 (71.3)
Unknown 5 (5.3)
Baseline b2 microglobulin
(at diagnosis)
< 3.5 mg/L 66 (70.2)
$ 3.5 mg/L 27 (28.7)
Unknown 1 (1.1)
Baseline LDH
(at diagnosis)
# 190 U/L 72 (76.6)
> 190 U/L 21 (22.3)
Unknown 1 (1.1)
Baseline cytogenetics
(at diagnosis)
Normal 55 (58.5)
Abnormal 39 (41.5)
*Patients were staged using the Durie & Salmon classification.
14 Biol Blood Marrow Transplant 15:12-20, 2009A. C. Sherman et al.dexamethasone) and DCEP. Stem cell collection oc-
curred after CAD. Patients were randomized to thalid-
omide or no thalidomide and then proceeded to
tandem autologous HSCT with melphalan 200 mg/
m2, followed by consolidation (DCEP) and mainte-
nance treatment. Twenty-three percent were enrolled
in a DT-PACE (dexamethasone, thalidomide, cis-
platin, doxorubicin, cyclophosphamide, and etopo-
side) protocol [15], designed for individuals with
a previous history of treatment; these patients received
2 cycles of DT-PACE. Those achieving at least a 50%
reduction in paraprotein were randomized to tandem
HSCT or to 4 more cycles of DT-PACE, followed
by maintenance treatment. A small number of partici-
pants (n 5 19) were treated with other protocols
(14.9%) or off protocol (5.3%). The study was ap-
proved by the Myeloma Institute for Research and
Therapy’s Institutional Review Board.
Procedure
Participants were recruited in the apheresis clinic
as they prepared to undergo stem cell collection, at
which time they signed a consent statement and com-
pleted baseline questionnaires. They completed a sec-
ond packet of questionnaires approximately 10 days
after undergoing HSCT (mean, 9.4 SD5 5.1 days),
when toxicities were expected to be more intensive.
This assessment occurred an average of 3.4 months
(SD 5 2.9 months) after the initial evaluation. Most
of the patients (n 5 82; 87.2%) were assessed aftertheir first transplantation, and 12 (12.8%) were evalu-
ated during a subsequent transplantation (including 3
who had undergone previous HSCT before enroll-
ment). The effects of single versus multiple transplan-
tations were included in the analyses (see Results).
Measures included the following:
Functional Assessment of Cancer Therapy–Bone
Marrow Transplant (FACT-BMT). HRQOL was mea-
sured by the FACT-BMT [16], which has been widely
used in oncology research. This instrument includes 4
subscales assessing physical, functional, social/family,
and emotional well-being. These scores are summed
to generate the FACT-G. An additional module, the
FACT-BMT scale, assesses concerns specific to
HSCT. Selected items are reverse-coded, so that
higher scores indicate better functioning. Items mea-
suring pain (1 item from the physical well-being scale)
and fatigue (mean of 2 items, 1 each from the physical
well-being and BMT scales; coefficient a 5 0.70) also
were of particular interest. Both the FACT-G and the
FACT-BMT modules have demonstrated good
internal consistency, criterion validity, and sensitivity
to change [16]. Norms are available for the general
population [17] and for patients undergoing BMT
[16]. The transplantation patient norms were derived
from individuals with diverse malignancies and induc-
tion regimens, so comparisons should be interpreted
with caution. In the current sample, the reliability of
each of the subscales was adequate, with coefficient
a ranging from 0.74 to 0.90 over the course of the 2 as-
sessment periods.
Brief Symptom Inventory (BSI). The BSI [18] anx-
iety and depression scales were used to assess general
psychological distress. This measure has been used fre-
quently among cancer patients and HSCT recipients;
its psychometric properties are well established [18].
A T score $ 60 was used as the cutoff for clinically
meaningful distress, based on sex-adjusted norms
from nonpsychiatric patients [18]. In the current sam-
ple coefficient a ranged from 0.79 to 0.87 for the 2 as-
sessments.
Impact of Event Scale (IES). The IES [19] was
used to measure cancer-specific stress. This instru-
ment generates scores for intrusive and avoidant symp-
toms; participants responded based on their experience
with myeloma. The measure is commonly used in on-
cology settings and has adequate psychometric proper-
ties [19]. The total score was used in the current study
in view of the high correlations between the subscales
(r 5 0.77). Scores $ 20 were considered indicative of
high stress, in accord with previous research. Coeffi-
cient a ranged from 0.89 to 0.92.
Satisfaction with Life Scale (SWLS) The afore-
mentioned measures of distress were supplemented
by a measure of positive adjustment: overall life
Biol Blood Marrow Transplant 15:12-20, 2009 15Quality-of-Life in Multiple Myeloma Patientssatisfaction, which was evaluated with the SWLS [20].
Studies have supported this scale’s reliability and con-
struct validity [20], and it has been used with HSCT
patients [21]. In the current study, coefficient a ranged
from 0.83 to 0.86.
Demographic and Medical Data Each patient
completed a form regarding demographic characteris-
tics and medical comorbidities. Clinical information
(eg, stage, time since diagnosis, recurrence status,
treatment protocol) was abstracted from medical re-
cords.
Data Analyses
Descriptive statistics were used to summarize the
outcome measures at both assessment intervals: stem
cell collection (apheresis) and posttransplantation.
To help interpret HRQOL findings, we evaluated
the percentage of participants whose FACT scores de-
viated from age- and sex-adjusted healthy population
norms by 1 standard deviation (SD) [17]. In addition,
effect sizes were calculated to characterize the differ-
ence in FACT scores between the myeloma patients
and population norms. These effects were interpreted
following Cohen’s [22] established guidelines (ie, 0.2 is
considered small, 0.5 is considered moderate, and 0.8
is considered large). In addition to healthy population
norms, FACT scores were compared with norms from
BMT patients [16], using effect sizes and 1-sample
t-tests. Given the particular significance of pain and
fatigue in myeloma patients, we also noted the
percentage who scored high (ie, indicating at least
‘‘somewhat’’ of a problem) on these items, although
no norms are available for them.Table 2. QOL and Psychosocial Outcomes Assessed at Stem Cell
from the General Population
Stem Cell Collection
% Exceeding Effect
Measure Mean (SD) Exceeding Cutoff* Effect
FACT-G 73.97 (14.76) 31.9 0
FACT physical
well-being
16.45 (5.82) 70.2 1
FACT functional
well-being
15.39 (5.73) 57.5 1
FACT social
well-being
23.96 (3.75) 2.1 1
FACTemotional
well-being
18.17 (4.12) 19.2 0
FACT-BMT scale 25.22 (5.93) — —
FACT pain item 2.57 (1.14) 39.4 —
FACT fatigue items 1.38 (0.92) 94.7 —
BSI anxiety 0.68 (0.68) 39.4 0
BSI depression 0.48 (0.60) 40.4 0
IES 18.09 (13.09) 37.0 —
Life Satisfaction 25.54 (6.51) — —
Note. Higher scores indicate better functioning on the FACTand Life Satisfac
*Percent of patients exceeding cutoff values, adjusted for age and sex for the
†Effect sizes based on comparisons with healthy population norms. (Missing val
for those scales.)To help interpret the psychosocial outcomes, we
evaluated the percentages of patients reporting clini-
cally meaningful distress on the IES (using established
cutoff scores [19]) and on the BSI anxiety and depres-
sion scales (using sex-adjusted population norms [18]).
Effect sizes are reported regarding comparisons be-
tween myeloma patients and population norms on
the BSI.
Changes in the outcomes over time (pretransplan-
tation to posttransplantation) were evaluated using
paired t-tests. To determine whether outcomes were
predicted by clinical or demographic variables, these re-
lationships were assessed using Pearson product-
moment correlations, t-tests, or analyses of variance,
as appropriate. Variables significantly associated with
our primary outcomes, overall HRQOL (FACT-G)
and psychosocial distress (depression), in bivariate anal-
yses were evaluated further using multiple regression.
Square-root transformations were used to correct skew-
ness in the BSI and IES scores. All tests were 2-tailed; P
values\ .05 were considered significant. Power was
sufficient (0.84) to detect moderately small effect sizes
(r5 0.30). Moreover, power was adequate (0.96) to de-
tect changes over time of 2 points on the FACT scales
using paired t-tests [16]. Previous research has identi-
fied 2 points as the ‘‘minimally important difference’’
(ie, reflecting clinically meaningful change) [23].RESULTS
HRQOL Outcomes
Table 2 lists descriptive statistics for the HRQOL
outcomes (FACT scales) at each assessment,Collection and at Posttransplantation Compared with Norms
Posttransplantation
% Exceeding Effect
Size† Mean (SD) Exceeding Cutoff* Effect Size†
.76 71.31 (15.37) 43.6 0.91
.46 15.06 (6.44) 76.6 1.50
.03 14.39 (5.86) 67.0 1.18
.05 23.56 (4.50) 3.2 0.78
.26 18.27 (3.85) 16.0 0.25
23.84 (6.57) — —
2.96 (1.06) 30.9 —
1.38 (0.92) 89.4 —
.53 0.76 (0.76) 44.7 0.56
.37 0.63 (0.63) 48.4 0.56
17.91 (15.42) 41.5 —
22.31 (7.48) — —
tion scales and worse functioning on the BSI and IES.
FACT scales and for sex for the BSI.
ues indicate absence of normative data to calculate cutoffs or effect sizes
16 Biol Blood Marrow Transplant 15:12-20, 2009A. C. Sherman et al.pretransplantation and posttransplantation. The table
also reports the percentage of patients who exceeded
cutoff scores in each domain (ie, $ 1 SD, indicating
notable problems) relative to age- and sex-adjusted
population norms. Overall, the prevalence of HRQOL
deficits was high at both assessment intervals, espe-
cially in the physical and functional domains.
Effect size estimates were small for emotional well-
being (0.25 to 0.26) and large for all other domains
(0.76 to 1.50). An interesting exception was seen in
the social well-being scale; the myeloma patients
scored better than the healthy reference population,
corresponding to a large effect (1.05) at stem cell collec-
tion and a moderate effect (0.78) posttransplantation.
As an additional basis for comparison, Table 3 lists
norms from transplantation patients with diverse diag-
noses assessed before and after HSCT (ie, transplanta-
tion patient norms) [16]. At stem cell collection, the
patients in the current study scored significantly worse
in 3 of 5 domains: physical well being, functional well
being, and BMT-specific concerns. The effect size was
large for physical well-being (0.88) and small for func-
tional well-being and BMT-specific concerns (0.40 to
0.45). In contrast, the myeloma patients reported sig-
nificantly better emotional well-being relative to these
norms (effect size, 0.72). At posttransplantation, mye-
loma patients demonstrated significantly worse physi-
cal well-being (moderate effect size, 0.68) and BMT-
specific concerns (small effect size, 0.28) compared
with patient norms. Conversely, they scored signifi-
cantly better than the norms on emotional and social
well-being (small effect sizes, 0.48 to 0.49).Psychosocial Outcomes
Table 2 summarizes data on psychosocial adjust-
ment (ie, IES distress, BSI anxiety, BSI depression,
life satisfaction). A large proportion of patients
reported elevated cancer-related distress on the IES
at stem cell collection (37.0%) and posttransplantationTable 3. FACT-BMT Scores for Multiple Myeloma Patients Compa
and Posttransplantation
Pretransplantation
Multiple Myeloma BMT Norms*
(n 5 94) (n 5 182)
Measure Mean (SD) Mean (SD) P Value Effect
FACT physical
well-being
16.5 (5.8) 21.6 (5.3) > .000001 0.8
FACT functional
well-being
15.4 (5.7) 17.7 (5.5) > .001 0.4
FACT social
well-being
24.0 (3.7) 24.0 (3.8) .91 0.0
FACTemotional
well-being
18.2 (4.2) 15.2 (3.1) > .000001 0.7
FACT-BMT scale 25.2 (5.9) 27.9 (5.4) > .0001 0.4
Note. Higher scores indicate better functioning on all scales.
*McQuellon et al., 1997 [16].(41.5%). Moreover, many reported clinically mean-
ingful levels of anxiety and depression at stem cell
collection (39.4% to 40.4%) and posttransplantation
(44.7% to 48.4%).
The average scores for anxiety and depression were
notably worse than the healthy population norms at
both assessments. Before transplantation, the effect
size was small for depression (0.37) and moderate for
anxiety (0.53), while after HSCT, both of these effect
sizes were moderate (0.56).
Changes Over Time
We expected to find declines in functioning in the
acute aftermath of transplantation. On the FACT
scales, patients reported a significant deterioration on
the BMT module from stem cell collection to the post-
transplantation period (P \ .05) (Table 2). On the
other hand, pain scores improved (P\ .01). The effect
sizes for these changes were small (0.23 to 0.34). With
respect to psychosocial outcomes, patients experi-
enced a significant worsening of depression (P\ .05;
effect size, 0.25) and life satisfaction (P\ .001; effect
size, 0.50) (Table 2).
Clinical and Demographic Predictors of
Outcomes
At stem cell collection, younger age (coded as
a continuous variable) was modestly correlated with
poorer functioning on several scales, including the
FACT-G (r 5 0.28; P\ .01), emotional well-being
(r 5 0.21; P\ .05), social well-being (r 5 0.28; P\
.05), physical well-being (r 5 0.21; P \ .05), pain
(r 5 0.26; P\ .05), BSI depression (r 5 -0.25; P\
.05), IES distress (r5 -0.23; P\ .05), and life satisfac-
tion (r 5 0.34; P \ .01) measures. Those with less
education reported more problems with fatigue
(r5 -0.24; P\ .05) at stem cell collection. The few pa-
tients who had undergone previous HSCT experi-
enced less anxiety (P \ .05) posttransplantation.red with BMT Patient Norms, Assessed at Pretransplantation
Posttransplantation
Multiple Myeloma BMT Norms*
(n 5 94) (n 5 74)
Size Mean (SD) Mean (SD) P Value Effect Size
8 15.1 (6.6) 19.5 (4.8) > .000001 0.68
0 14.4 (5.9) 14. 5(5.3) .86 0.02
1 23.6 (4.9) 21.4 (3.6) > .00001 0.48
2 18.3 (3.9) 16.4 (3.2) > .00001 0.49
5 23.8 (6.6) 25.7 (5.3) > .01 0.28
Biol Blood Marrow Transplant 15:12-20, 2009 17Quality-of-Life in Multiple Myeloma PatientsPatients treated with thalidomide reported poorer
functional well-being (P 5 .01) and FACT-G (P \
.05) scores at stem cell collection, as well as poorer
functional well-being (P\ .05), social well-being (P
\ .01), and life satisfaction (P\ .01) after transplanta-
tion. Those with an elevated lactate dehydrogenase
(LDH) level (.190 U/L) at baseline had greater
depression (P\ .05) and anxiety (P\ .05) before trans-
plantation, along with greater depression after trans-
plantation (P\ .05). None of the other demographic
(eg, sex, marital status) or clinical variables (eg, stage,
treatment protocol, time since diagnosis, number of
comorbidities) were significantly related to outcomes.
Multiple regression analyses were used to model
variables associated with our primary outcomes
(FACT-G; depression) in bivariate analyses. Poorer
FACT-G scores at stem cell collection were predicted
by both younger age (b5 .26) and treatment with tha-
lidomide (b 5 .20) [F (2,91) 5 6.11; P\ .01; R2 5
0.12]. Greater depression at stem cell collection was
significantly predicted by younger age (b 5 -0.21)
and marginally predicted by higher baseline LDH
(b 5 0.17) [F(2,90) 5 4.23; P\ .05; R2 5 0.09]. (Re-
gression analyses were not used to model posttrans-
plantation outcomes, because bivariate analyses did
not reveal more than 1 predictor for these outcomes.)
Secondary analyses were conducted to further
ensure that older patients were not at increased risk
for poor outcomes. T-tests confirmed that patients
age 65 and older did not fare more poorly than youn-
ger ones indeed, they scored better on the FACT phys-
ical well-being (P\ .05), social well-being (P\ .05),
functional well-being (P\ .05), and FACT-G (P\
.01) scales at stem cell collection, and on the social
well-being scale at posttransplantation (P\ .05).DISCUSSION
Although notable progress has been made in study-
ing QOL outcomes in patients undergoing autologous
HSCT [24,25], many of the previous investigations
included participants with a wide range of malignan-
cies. The use of heterogeneous samples obscures find-
ings that are unique to a specific disease. In particular,
few studies have examined the challenges faced by
patients with myeloma [5,12,26], although the charac-
teristic symptoms and disease trajectory of myeloma
differ from those of other hematologic malignancies.
Prospective investigations that have included patients
with other illnesses undergoing autologous HSCT of-
ten have relied on small samples [21,27,28], and few
have focused on the acute posttransplantation period,
during which toxicities are most demanding
[24,26,28,29]. Moreover, few studies have sought indi-
cators of clinical (rather than only statistical) signifi-
cance, by drawing on norms, cutoff values, and effect
size estimates to aid in interpreting findings [7,12].The current investigation suggests that myeloma
patients experience extensive functional and psychoso-
cial difficulties both during induction chemotherapy
and in the immediate aftermath of transplantation.Physical Domains
At stem cell collection, problems were most pro-
nounced in physical domains of functioning (ie, phys-
ical and functional well-being). The average scores of
myeloma patients were considerably worse than age-
and sex-adjusted population norms [17], as highlighted
by the large effect sizes. In terms of prevalence esti-
mates, the majority of participants scored well-below
population norms (1 SD) for physical well-being
(70%) and functional well-being (58%), and many
experienced difficulties with at least moderate fatigue
(95%) and pain (39%).
The high level of symptom burden also was evident
when participants were compared with transplantation
norms, derived from patients with mixed malignancies
assessed prior to undergoing HSCT [16]. In another
study of patients evaluated prior to HSCT, Larsen
et al. [30] similarly found that myeloma patients had
worse HRQOL than other diagnostic groups,
although the samples were small. Anderson et al. [13]
reported that myeloma patients experienced worse
pain, but less sleep disturbance and fatigue, than
patients with non-Hodgkin lymphoma before HSCT.
These studies begin to highlight some of the hardships
specifically related to myeloma.
As expected, patients reported some further de-
clines in physical functioning immediately following
undergoing high-dose therapy and HSCT, when
they were confronted by heightened toxicities. Trans-
plantation-related concerns (FACT-BMT module)
became significantly worse, and overall QOL
(FACT-G) showed a marginal deterioration. Overall,
however, these changes were not as pronounced as ex-
pected and were of questionable clinical significance
(eg,\ 2-point change in FACT-BMT scores). More-
over, the magnitude of these declines did not appear to
be as great as the decrements experienced by the trans-
plant reference group [16]. Perhaps the experience of
myeloma patients in the posttransplantation period
was buffered by improvements in pain and, more
broadly, by the extensive supportive care provided by
a specialized transplantation team.
Psychosocial Domains
Evaluation of the psychosocial dimensions of
HRQOL demonstrated a different pattern than the
physical dimensions. At stem cell collection, the mye-
loma patients reported better social well-being than
both healthy individuals [17] and other transplant
recipients [16]. There was little change in these scores
following HSCT. The reasons for these patients’
18 Biol Blood Marrow Transplant 15:12-20, 2009A. C. Sherman et al.favorable social functioning are unclear, but the trans-
plantation program requires the involvement of an in-
formal caregiver (family or friend) to assist each patient
through the process, and considerable psychosocial
support services are available.
Although social functioning was well preserved,
emotional adjustment was more problematic. Turning
from the FACT scores to more specific, clinically
relevant measures of distress, it is evident that difficul-
ties were common in this area. Prevalence estimates
suggested that 39% to 40% of patients experienced
clinically meaningful levels of anxiety and depression
at stem cell collection. After HSCT, the prevalence
rates rose somewhat (45% to 48%), and the effect sizes
(relative to population norms) became a bit stronger.
Significant adverse changes in depression and life
satisfaction were evident. These findings indicate
that emotional distress during treatment is an impor-
tant concern for a number of patients.
Clearly, more research is needed to track patients
beyond the critical periods addressed in the present
study in order to determine changes over the long
term. Previous studies by the Nordic Myeloma Study
Group [5-7] and Uyl-de Groot et al. [26] suggest
that diminished HRQOL in the aftermath of HSCT
is followed by progressive improvements (exceeding
baseline levels) over time, although areas of residual
difficulty remain. However, neither of these investiga-
tions focused specifically on psychosocial adjustment
which might follow a different trajectory.
Our findings have some important clinical implica-
tions. The improvements in pain, in conjunction with
well-preserved social well-being and relatively modest
declines in physical functioning, are heartening. Nev-
ertheless, it is evident that myeloma patients face con-
siderable burdens during their course of HSCT.
Interdisciplinary supportive care services play a salient
role in the treatment of these patients. Various practice
guidelines, such as those developed by the National
Comprehensive Cancer Network [31,32], call for rou-
tine screening and early intervention for a number of
QOL concerns. Previous studies by our group and
others indicate that screening programs are feasible
in busy transplantation centers [10,11,33]. Moreover,
ongoing advances in supportive care are expanding
the range of interventions available to improve QOL
(eg, kyphoplasty, colony-stimulating factors, psycho-
logical services, exercise regimens).
Differences Across Clinical and Demographic
Subgroups of Patients
Which patients are most at risk for QOL difficul-
ties? There have been concerns about the capacity of
older patients to tolerate transplantation protocols,
and earlier clinical trials excluded those over age 60
or 65. More recent studies have suggested that trans-
plantation is feasible for older patients, however[8,9,34]. At our center, the melphalan dose during
high-dose therapy is reduced from 200 to 140 mg/m2
for patients age 70 and older [8], and some other centers
make similar dose adjustments [9]. The current study
provided no indications that older patients were at
elevated risk for QOL deficits. Indeed, older age was
correlated with fewer physical symptoms and less
pain during stem cell collection and with consistently
better (albeit modestly so) psychosocial outcomes.
These findings are consistent with those of studies in
the broader oncology literature, in which younger
patients often exhibit greater emotional difficulties
than older patients [35]. Thus, given appropriate
dose adjustments, older patients appear to be able to
weather HSCT at least as well as their younger coun-
terparts.
Thalidomide was associated with greater difficul-
ties in a number of areas, which perhaps is not surpris-
ing in view of its well-recognized toxicities (eg,
peripheral neuropathy, sedation, constipation). Alter-
ations in dosing and scheduling, along with the
availability of better-tolerated second-generation im-
munomodulatory agents (eg, lenalidomide), now pro-
vide additional treatment options. Other demographic
and medical variables did not have a major impact on
the endpoints assessed. Elevated LDH, a marker of
disease status, was associated with greater distress.
This finding was not anticipated and should be inter-
preted cautiously, but the relationship merits attention
in further research. In a previous investigation, LDH
was not related to overall symptom burden, but no
analyses were reported that focused specifically on
psychosocial symptoms [12]. Previous studies have
demonstrated highly variable findings regarding other
clinical and demographic correlates [11,12]. There is
a need to explore additional variables that might influ-
ence outcomes, drawn from richer conceptual and em-
pirical foundations, such as personal resources (eg,
optimism), coping responses (eg, active coping, mean-
ing-making), and social context (eg, cultural beliefs). A
separate paper examined religious coping in this co-
hort [36].
Strengths of the present study include use of a pro-
spective design and validated measures to assess multi-
ple dimensions of HRQOL and psychosocial
adjustment over the course of induction therapy and
transplantation. The study has some notable limita-
tions, however. Although the patients were evaluated
at critical phases of treatment (stem cell harvest and
posttransplantation), outcomes need to be evaluated
over more extended periods as well, including mainte-
nance therapy and long-term follow-up, during which
functioning would be expected to improve. Such eval-
uations are underway at our center. Myeloma treat-
ment is evolving rapidly, and it will be critical to
assess the impact of newer agents (eg, bortezomib, le-
nalidomide), particularly as they are integrated with
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assess all eligible patients treated at our facility; none-
theless, there are no indications that the sample was bi-
ased relative to the broader pool of patients. The
current investigation represents the experience of a sin-
gle institution, and it is unclear how findings would
generalize to other treatment centers (that differ in
terms of treatment intensity, referral patterns, racial
diversity, etc.). Finally, norms were used to help inter-
pret the findings; this provided a useful context that
few previous studies have offered. Inevitably, however,
the comparisons are imperfect. The transplantation
reference group [16] was relatively small and included
patients who had undergone diverse treatments for
varying diseases; thus, the factors accounting for the
observed differences in HRQOL (eg, effects of diag-
nosis, treatment, or other variables) remain unclear.
Moreover, in that study [16], the posttransplantation
evaluation occurred at hospital discharge; the number
of days after HSCT was not specified, but presumably
this interval was slightly longer than that in our inves-
tigation (mean, 9 days). Thus, our comparisons may
overestimate the magnitude of true differences in
HRQOL somewhat (because our patients might have
experienced fewer difficulties with a longer recovery
period).
Notwithstanding these limitations, however, our
findings suggest that myeloma patients contend with
considerable symptom burden over the course of
induction therapy and HSCT. Physical domains of
functioning are notably disrupted during induction
therapy. Importantly, however, the deterioration in
physical functioning after high-dose therapy and
HSCT appears to be less extensive than expected.
Social and emotional well being seem to be well pre-
served in most patients, but a sizeable minority experi-
ence elevated levels of distress both prior to and
immediately following HSCT. These findings under-
score the need for screening and early intervention.ACKNOWLEDGMENTS
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